Revenue
Cost
Profit
| Item | Category | Value | YoY |
|---|---|---|---|
| Revenues: | revenue | 14.45B | 5.37% |
| Income from continuing operations before provision/(benefit) for taxes on income | profit | 3.17B | 13.82% |
| Cost of sales | cost | 3.55B | 24.71% |
| Selling, informational and administrative expenses | cost | 2.96B | -2.31% |
| Research and development expenses | cost | 2.49B | 13.03% |
| Amortization of intangible assets | cost | 1.18B | -2.31% |
| Other nonoperating income (expense) | revenue | 861.00M | -9.65% |
| Acquired in-process research and development expenses | cost | 137.00M | 1422.22% |
| Restructuring charges and certain acquisition-related costs | cost | 100.00M | -85.25% |
| Net income from continuing operations before allocation to noncontrolling interests | profit | 2.71B | -8.88% |
| Provision/(benefit) for taxes on income | cost | 461.00M | 143.92% |
| Net income before allocation to noncontrolling interests | profit | 2.70B | -9.32% |
| Discontinued operations––net of tax | revenue | 13.00M | |
| Net income attributable to pfizer inc. common shareholders | profit | 2.69B | -9.44% |
| Less: net income attributable to noncontrolling interests | cost | 8.00M | 33.33% |
| Segment | Value | YoY |
|---|---|---|
| Biopharma | 14.16B | 5.36% |
| Others | 290.00M | 5.84% |
| Segment | Value | YoY |
|---|---|---|
| UNITED STATES | 8.73B | 4.26% |
| International Developed Markets | 3.43B | 7.80% |
| International Emerging Markets | 2.29B | 6.01% |
| Others | 1.00M |
| Segment | Value | YoY |
|---|---|---|
| Product | 11.71B | 3.73% |
| Royalty | 396.00M | 28.57% |
| Others | 2.34B | 10.74% |
| Item | Category | Value | YoY |
|---|---|---|---|
| Trade accounts receivable, net of allowance for doubtful accounts: 2026—$425; 2025—$427 | assets | 12.59B | |
| Short-term investments | assets | 11.37B | |
| Inventories | assets | 10.67B | |
| Current tax assets | assets | 3.59B | |
| Other assets, current | assets | 2.91B | |
| Cash and cash equivalents | assets | 1.70B | |
| Total current assets | assets | 42.82B | |
| Goodwill | assets | 71.41B | |
| Identifiable intangible assets, less accumulated amortization | assets | 52.56B | |
| Property, plant and equipment, net of accumulated depreciation: 2026—$17,803; 2025—$17,386 | assets | 19.40B | |
| Noncurrent deferred tax assets and other noncurrent tax assets | assets | 9.96B | |
| Other assets, noncurrent | assets | 9.83B | |
| Long-term investments | assets | 1.63B | |
| Total assets | assets | 207.62B | |
| Total liabilities | liabilities | 117.21B | |
| Total equity | liabilities | 90.40B | |
| Long-term debt | liabilities | 60.56B | |
| Total current liabilities | liabilities | 34.35B | |
| Other noncurrent liabilities | liabilities | 14.20B | |
| Other taxes payable | liabilities | 3.71B | |
| Noncurrent deferred tax liabilities | liabilities | 2.41B | |
| Pension and postretirement benefit obligations | liabilities | 1.98B | |
| Equity attributable to noncontrolling interests | liabilities | 303.00M | |
| Total pfizer inc. shareholders’ equity | equity | 90.10B | |
| Treasury stock, common, value | equity | 115.19B | |
| Accumulated other comprehensive loss | equity | 7.20B | |
| Other liabilities, current | liabilities | 20.11B | |
| Trade accounts payable | liabilities | 4.51B | |
| Total short-term borrowings, including current portion of long-term debt, carried at historical proceeds, as adjusted | liabilities | 3.89B | |
| Income taxes payable | liabilities | 3.13B | |
| Accrued compensation and related items | liabilities | 2.71B | |
| Aggregate | equity | 212.49B | |
| Retained earnings | equity | 117.24B | |
| Additional paid-in capital | equity | 94.77B | |
| Common stock | equity | 482.00M |
| Item | Value |
|---|---|
| Net income from continuing operations before allocation to noncontrolling interests | 2.71B |
| Depreciation and amortization | 1.61B |
| Share-based compensation expense | 272.00M |
| Asset write-offs and asset impairment charges | 32.00M |
| Deferred income tax expense (benefit) | -12.00M |
| Other noncash income (expense) | -93.00M |
| Pension and other postretirement benefit contributions, net of pension and other postretirement benefit (expense) | -173.00M |
| Adjustment to reconcile net income to cash provided by (used in) operating activity, increase (decrease) in operating capital | -1.73B |
| Item | Value |
|---|---|
| Proceeds from redemptions/sales of short-term investments | 4.58B |
| Proceeds from redemptions/sales of long-term investments | 88.00M |
| Payment for (proceeds from) other investing activity | 22.00M |
| Payments to acquire marketable securities | -104.00M |
| Payments to acquire property, plant, and equipment | -436.00M |
| Payments for (proceeds from) short term investments with original maturities of three months or less | -792.00M |
| Payments to acquire short-term investments | -2.57B |
| Item | Value |
|---|---|
| Net (payments on)/proceeds from short-term borrowings with original maturities of three months or less | -127.00M |
| Other financing activities, net | -284.00M |
| Payments of ordinary dividends | -2.44B |
| Item | Value |
|---|---|
| Cash and cash equivalents, beginning of period | 1.20B |
| Cash and cash equivalents, end of period | 1.76B |
Instantly decode complex 10-K and 10-Q data. Explore interactive Sankey diagrams for income and balance sheets, and intuitive waterfall charts for cash flows.
Search for a company and select a report on the left panel.
Request Stock Support